These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36997081)

  • 21. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
    Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
    Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
    Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
    Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year.
    Morrell KM; Cremers S; Westhoff CL; Davis AR
    Contraception; 2016 Mar; 93(3):263-5. PubMed ID: 26577754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.
    Bennink HJ
    Eur J Contracept Reprod Health Care; 2000 Sep; 5 Suppl 2():12-20. PubMed ID: 11246602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
    Lazorwitz A; Sheeder J; Teal S
    Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
    Duijkers I; Klipping C; Heger-Mahn D; Fayad GN; Frenkl TL; Cruz SM; Korver T
    Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):245-254. PubMed ID: 30203681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
    Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
    Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
    Romano ME; Braun-Courville DK
    J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
    Modesto W; Dal Ava N; Monteiro I; Bahamondes L
    Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients.
    Lew J; Sheeder J; Lazorwitz A
    Contraception; 2021 Nov; 104(5):556-560. PubMed ID: 34147509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
    Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of Implanon on lipid metabolism in comparison with Norplant.
    Suherman SK; Affandi B; Korver T
    Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial.
    Lombardi Fäh V; Catarino R; Castillo S; Badda M; Gezer-Dickschat S; Thieringer F; Tschudin S; Viviano M; Yaron M
    BMC Res Notes; 2023 Mar; 16(1):35. PubMed ID: 36915205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
    Kreitchmann R; Stek A; Best BM; Capparelli E; Wang J; Shapiro D; Chakhtoura N; Mirochnick M; Eke AC;
    Contraception; 2022 Jan; 105():67-74. PubMed ID: 34407424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
    Ferreira-Filho ES; Bahamondes L; Duarte DC; Guimarães ALM; de Almeida PG; Soares-Júnior JM; Baracat EC; Sorpreso ICE
    Gynecol Endocrinol; 2022 Jan; 38(1):90-93. PubMed ID: 34486922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
    Wenzl R; van Beek A; Schnabel P; Huber J
    Contraception; 1998 Nov; 58(5):283-8. PubMed ID: 9883383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.